Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification

Overview

Journal J Pers Med

Date 2021 Oct 23

PMID 34683183

Authors

Cati Raluca Stolniceanu

Mihaela Moscalu

Doina Azoicai

Bogdan Tamba

Constantin Volovat

Irena Grierosu

Teodor Ionescu

Wael Jalloul

Vlad Ghizdovat

Roxana Gherasim

Simona Volovat

Feng Wang

Jingjing Fu

Roxana Moscalu

Milovan Matovic

Cipriana Stefanescu

Affiliations

Soon will be listed here.

Abstract

Although neuroendocrine tumours (NETs) are intensively studied, their diagnosis and consequently personalised therapy management is still puzzling due to their tumoral heterogeneity. In their theragnosis algorithm, receptor somatostatin scintigraphy takes the central place, the diagnosis receptor somatostatin analogue (RSA) choice depending on laboratory experience and accessibility. However, in all cases, the results depend decisively on correct radiotracer tumoral uptake quantification, where unfortunately there are still unrevealed clues and lack of standardization. We propose an improved method to quantify the biodistribution of gamma-emitting RSA, using tissular corrected uptake indices. We conducted a bi-centric retrospective study on 101 patients with different types of NETs. Three uptake indices obtained after applying new corrections to areas of interest drawn for the tumour and for three reference organs (liver, spleen and lung) were statistically analysed. For the corrected pathological uptake indices, the results showed a significant decrease in the error of estimating the occurrence of errors and an increase in the diagnostic predictive power for NETs, especially in the case of lung-referring corrected index. In conclusion, these results support the importance of corrected uptake indices use in the analysis of TcRSA biodistribution for a better personalised diagnostic accuracy of NETs patients.

References

deSouza N, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clement O . Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging. 2019; 10(1):87. PMC: 6715762. DOI: 10.1186/s13244-019-0764-0. View

Opalinska M, Hubalewska-Dydejczyk A, Sowa-Staszczak A, Stefanska A . NEN - the role of somatostatin receptor scintigraphy in clinical setting. Nucl Med Rev Cent East Eur. 2016; 19(2):118-25. DOI: 10.5603/NMR.2016.0023. View

Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather S . An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003; 44(5):708-16. View

Baldelli R, Barnabei A, Rizza L, Isidori A, Rota F, Di Giacinto P . Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014; 5:7. PMC: 3916777. DOI: 10.3389/fendo.2014.00007. View

Alevroudis E, Spei M, Chatziioannou S, Tsoli M, Wallin G, Kaltsas G . Clinical Utility of F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021; 13(8). PMC: 8069875. DOI: 10.3390/cancers13081813. View

Boellaard R, ODoherty M, Weber W, Mottaghy F, Lonsdale M, Stroobants S . FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2009; 37(1):181-200. PMC: 2791475. DOI: 10.1007/s00259-009-1297-4. View

Decristoforo C, Mather S, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R . 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000; 27(9):1318-25. DOI: 10.1007/s002590000289. View

Stolniceanu C, Nistor I, Bilha S, Constantin V, Simona V, Matovic M . Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nucl Med Commun. 2020; 41(7):601-617. DOI: 10.1097/MNM.0000000000001198. View

Groshar D, Bernstine H, Goldberg N, Nidam M, Stein D, Abadi-Korek I . Reproducibility and repeatability of same-day two sequential FDG PET/MR and PET/CT. Cancer Imaging. 2017; 17(1):11. PMC: 5381130. DOI: 10.1186/s40644-017-0113-9. View

10.

Waldmann C, Stuparu A, van Dam R, Slavik R . The Search for an Alternative to [Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of F-labeled Somatostatin Analog Development. Theranostics. 2019; 9(5):1336-1347. PMC: 6401503. DOI: 10.7150/thno.31806. View

11.

Briganti V, Cuccurullo V, Berti V, Di Stasio G, Linguanti F, Mungai F . Tc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases). Curr Radiopharm. 2019; 13(3):166-176. PMC: 8193811. DOI: 10.2174/1874471013666191230143610. View

12.

Jahn U, Ilan E, Sandstrom M, Lubberink M, Garske-Roman U, Sundin A . Peptide Receptor Radionuclide Therapy (PRRT) with Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. Cancers (Basel). 2021; 13(5). PMC: 7956792. DOI: 10.3390/cancers13050962. View

13.

La Salvia A, Espinosa-Olarte P, Del Carmen Riesco-Martinez M, Anton-Pascual B, Garcia-Carbonero R . Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?. Cancers (Basel). 2021; 13(7). PMC: 8038369. DOI: 10.3390/cancers13071701. View

14.

Pedraza-Arevalo S, Gahete M, Alors-Perez E, Luque R, Castano J . Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord. 2018; 19(2):179-192. DOI: 10.1007/s11154-018-9465-0. View

15.

Taieb D, Garrigue P, Bardies M, Abdullah A, Pacak K . Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. PET Clin. 2015; 10(4):477-86. PMC: 4617555. DOI: 10.1016/j.cpet.2015.06.001. View

16.

Graf J, Pape U, Jann H, Denecke T, Arsenic R, Brenner W . Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2019; 47(4):881-894. DOI: 10.1007/s00259-019-04439-9. View

17.

Cwikla J, Mikolajczak R, Pawlak D, Buscombe J, Nasierowska-Guttmejer A, Bator A . Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs. J Nucl Med. 2008; 49(7):1060-5. DOI: 10.2967/jnumed.107.046961. View

18.

Buckler A, Bresolin L, Reed Dunnick N, Sullivan D, Aerts H, Bendriem B . Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. Radiology. 2011; 259(3):875-84. PMC: 5410955. DOI: 10.1148/radiol.10100800. View

19.

Herrera-Martinez A, Hofland J, Hofland L, Brabander T, Eskens F, Galvez Moreno M . Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs. 2018; 79(1):21-42. PMC: 6338796. DOI: 10.1007/s40265-018-1033-0. View

20.

Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, Maecke H, Huszno B, Pach D . 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006; 33(10):1123-33. DOI: 10.1007/s00259-006-0113-7. View